1-Year Trastuzumab Regimen Yields DFS in ERBB2+ Breast Cancer
Patients with ERBB2-positive breast cancer who were being treated with chemotherapy and who received 1 year of adjuvant trastuzumab (Herceptin) experienced improved disease-free survival (DFS) compared with patients who received 9 weeks of treatment, …